Insmed Incorporated (0JAV.L)
USD 71.8
(-4.53%)
USD 71.8
(-4.53%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -709.62 Million USD | -48.42% |
| 2022 | -478.12 Million USD | -30.01% |
| 2021 | -367.76 Million USD | -38.66% |
| 2020 | -265.23 Million USD | -12.75% |
| 2019 | -235.24 Million USD | 23.46% |
| 2018 | -307.33 Million USD | -62.68% |
| 2017 | -188.92 Million USD | -8.95% |
| 2016 | -173.4 Million USD | -47.58% |
| 2015 | -117.49 Million USD | -34.49% |
| 2014 | -87.36 Million USD | -58.8% |
| 2013 | -55.01 Million USD | -29.64% |
| 2012 | -42.43 Million USD | 31.24% |
| 2011 | -61.71 Million USD | -662.72% |
| 2010 | -8.09 Million USD | 6.71% |
| 2009 | -8.67 Million USD | 39.81% |
| 2008 | -14.41 Million USD | 29.49% |
| 2007 | -20.43 Million USD | 62.41% |
| 2006 | -54.37 Million USD | -98.2% |
| 2005 | -27.43 Million USD | -0.03% |
| 2004 | -27.42 Million USD | -159.07% |
| 2003 | -10.58 Million USD | 71.41% |
| 2002 | -37.02 Million USD | 7.87% |
| 2001 | -40.18 Million USD | 50.71% |
| 2000 | -81.53 Million USD | -902.86% |
| 1999 | -8.13 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -185.2 Million USD | -17.66% |
| 2024 Q1 | -157.4 Million USD | 11.71% |
| 2024 Q3 | -213.42 Million USD | -15.24% |
| 2023 Q2 | -235.52 Million USD | -49.39% |
| 2023 Q4 | -178.27 Million USD | -20.72% |
| 2023 Q3 | -147.66 Million USD | 37.3% |
| 2023 FY | -709.62 Million USD | -48.42% |
| 2023 Q1 | -157.65 Million USD | -2.86% |
| 2022 Q1 | -101.45 Million USD | -2.4% |
| 2022 FY | -478.12 Million USD | -30.01% |
| 2022 Q4 | -153.27 Million USD | -20.03% |
| 2022 Q3 | -127.69 Million USD | -44.59% |
| 2022 Q2 | -88.31 Million USD | 12.95% |
| 2021 FY | -367.76 Million USD | -38.66% |
| 2021 Q3 | -103.61 Million USD | -16.99% |
| 2021 Q4 | -99.07 Million USD | 4.38% |
| 2021 Q2 | -88.56 Million USD | -5.65% |
| 2021 Q1 | -83.83 Million USD | 11.32% |
| 2020 Q3 | -56.22 Million USD | -3.9% |
| 2020 Q1 | -60.35 Million USD | -28.2% |
| 2020 Q4 | -94.53 Million USD | -68.15% |
| 2020 Q2 | -54.11 Million USD | 10.34% |
| 2020 FY | -265.23 Million USD | -12.75% |
| 2019 Q2 | -62.16 Million USD | 10.56% |
| 2019 Q4 | -47.08 Million USD | 16.65% |
| 2019 FY | -235.24 Million USD | 23.46% |
| 2019 Q3 | -56.48 Million USD | 9.13% |
| 2019 Q1 | -69.5 Million USD | 20.76% |
| 2018 Q2 | -72.88 Million USD | -16.14% |
| 2018 Q1 | -62.75 Million USD | 3.98% |
| 2018 FY | -307.33 Million USD | -62.68% |
| 2018 Q4 | -87.72 Million USD | -4.45% |
| 2018 Q3 | -83.98 Million USD | -15.23% |
| 2017 FY | -188.92 Million USD | -8.95% |
| 2017 Q1 | -35.96 Million USD | 46.36% |
| 2017 Q4 | -65.35 Million USD | -48.25% |
| 2017 Q2 | -43.51 Million USD | -20.98% |
| 2017 Q3 | -44.08 Million USD | -1.31% |
| 2016 Q4 | -67.05 Million USD | -80.49% |
| 2016 Q3 | -37.14 Million USD | -2.81% |
| 2016 FY | -173.4 Million USD | -47.58% |
| 2016 Q1 | -33.06 Million USD | -1.46% |
| 2016 Q2 | -36.13 Million USD | -9.27% |
| 2015 Q3 | -30.24 Million USD | -8.2% |
| 2015 Q1 | -26.7 Million USD | -15.78% |
| 2015 Q4 | -32.59 Million USD | -7.75% |
| 2015 FY | -117.49 Million USD | -34.49% |
| 2015 Q2 | -27.95 Million USD | -4.67% |
| 2014 Q2 | -22.81 Million USD | -26.2% |
| 2014 Q4 | -23.06 Million USD | 1.44% |
| 2014 FY | -87.36 Million USD | -58.8% |
| 2014 Q1 | -18.07 Million USD | -15.94% |
| 2014 Q3 | -23.4 Million USD | -2.58% |
| 2013 Q1 | -14.3 Million USD | 9.65% |
| 2013 FY | -55.01 Million USD | -29.64% |
| 2013 Q4 | -15.59 Million USD | 7.41% |
| 2013 Q3 | -16.84 Million USD | -103.68% |
| 2013 Q2 | -8.26 Million USD | 42.21% |
| 2012 Q2 | -9.98 Million USD | -37.43% |
| 2012 Q1 | -7.26 Million USD | 18.11% |
| 2012 FY | -42.43 Million USD | 31.24% |
| 2012 Q4 | -15.83 Million USD | -69.34% |
| 2012 Q3 | -9.35 Million USD | 6.31% |
| 2011 FY | -61.71 Million USD | -662.72% |
| 2011 Q2 | -10.47 Million USD | -41.24% |
| 2011 Q1 | -7.41 Million USD | -17.14% |
| 2011 Q3 | -34.96 Million USD | -233.81% |
| 2011 Q4 | -8.87 Million USD | 74.63% |
| 2010 Q1 | -251 Thousand USD | -173.18% |
| 2010 Q4 | -6.33 Million USD | -958.53% |
| 2010 FY | -8.09 Million USD | 6.71% |
| 2010 Q2 | -913 Thousand USD | -263.75% |
| 2010 Q3 | -598 Thousand USD | 34.5% |
| 2009 Q4 | 343 Thousand USD | 144.9% |
| 2009 FY | -8.67 Million USD | 39.81% |
| 2009 Q2 | -1.3 Million USD | 81.2% |
| 2009 Q1 | -6.94 Million USD | -85.85% |
| 2009 Q3 | -764 Thousand USD | 41.5% |
| 2008 Q4 | -3.73 Million USD | -98.2% |
| 2008 Q2 | -4.43 Million USD | 7.57% |
| 2008 Q3 | -1.88 Million USD | 57.47% |
| 2008 Q1 | -4.79 Million USD | -43.48% |
| 2008 FY | -14.41 Million USD | 29.49% |
| 2007 Q4 | -3.34 Million USD | 18.89% |
| 2007 Q3 | -4.12 Million USD | -60.49% |
| 2007 Q2 | -2.56 Million USD | 75.31% |
| 2007 Q1 | -10.4 Million USD | 51.4% |
| 2007 FY | -20.43 Million USD | 62.41% |
| 2006 Q3 | -12.72 Million USD | -36.47% |
| 2006 Q2 | -9.32 Million USD | 14.62% |
| 2006 Q1 | -10.92 Million USD | -54.59% |
| 2006 Q4 | -21.4 Million USD | -68.22% |
| 2006 FY | -54.37 Million USD | -98.2% |
| 2005 Q1 | -5.52 Million USD | 6.12% |
| 2005 Q2 | -6.95 Million USD | -25.86% |
| 2005 FY | -27.43 Million USD | -0.03% |
| 2005 Q3 | -7.89 Million USD | -13.6% |
| 2005 Q4 | -7.06 Million USD | 10.54% |
| 2004 Q2 | -9.06 Million USD | -87.38% |
| 2004 Q1 | -4.83 Million USD | -93.09% |
| 2004 FY | -27.42 Million USD | -159.07% |
| 2004 Q3 | -7.64 Million USD | 15.6% |
| 2004 Q4 | -5.88 Million USD | 23.07% |
| 2003 Q1 | -2.3 Million USD | 87.64% |
| 2003 FY | -10.58 Million USD | 71.41% |
| 2003 Q4 | -2.5 Million USD | -1.46% |
| 2003 Q3 | -2.46 Million USD | 25.51% |
| 2003 Q2 | -3.31 Million USD | -43.98% |
| 2002 Q1 | -6.3 Million USD | 38.38% |
| 2002 Q2 | -7.27 Million USD | -15.37% |
| 2002 FY | -37.02 Million USD | 7.87% |
| 2002 Q4 | -18.62 Million USD | -287.03% |
| 2002 Q3 | -4.81 Million USD | 33.89% |
| 2001 FY | -40.18 Million USD | 50.71% |
| 2001 Q4 | -10.23 Million USD | -14.09% |
| 2001 Q3 | -8.97 Million USD | 6.8% |
| 2001 Q2 | -9.62 Million USD | 15.13% |
| 2001 Q1 | -11.34 Million USD | -26.49% |
| 2000 FY | -81.53 Million USD | -902.86% |
| 2000 Q4 | -8.96 Million USD | -61.75% |
| 2000 Q3 | -5.54 Million USD | 90.03% |
| 2000 Q1 | -11.42 Million USD | 0.0% |
| 2000 Q2 | -55.6 Million USD | -386.87% |
| 1999 Q1 | -1.58 Million USD | 0.0% |
| 1999 FY | -8.13 Million USD | 0.0% |
| 1999 Q2 | -1.67 Million USD | -6.08% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -319.448% |
| Dynavax Technologies Corporation | -37.02 Million USD | -1816.458% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -13367.945% |
| Perrigo Company plc | 151.9 Million USD | 567.167% |
| Illumina, Inc. | -1.06 Billion USD | 33.618% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 110.346% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | -54.079% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 94.959% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 135.894% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -541.528% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 117.534% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -1488.703% |
| Waters Corporation | 817.67 Million USD | 186.786% |
| Biogen Inc. | 1.29 Billion USD | 154.721% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -158.983% |
| Evolus, Inc. | -49.23 Million USD | -1341.363% |
| Adicet Bio, Inc. | -152.03 Million USD | -366.743% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -484.078% |
| bluebird bio, Inc. | -244.26 Million USD | -190.518% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -356.166% |
| FibroGen, Inc. | -281.81 Million USD | -151.806% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 152.565% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -1474.242% |
| Homology Medicines, Inc. | -48.25 Million USD | -1370.575% |
| Geron Corporation | -193.94 Million USD | -265.892% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -151.484% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -865.556% |
| Myriad Genetics, Inc. | -123.7 Million USD | -473.667% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -603.806% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | -37.714% |
| Zoetis Inc. | 3.06 Billion USD | 123.122% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -1372.253% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 165.266% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 464.957% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 116.474% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -1712.443% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -100.612% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -157.105% |
| Verastem, Inc. | -92.08 Million USD | -670.629% |
| Nektar Therapeutics | -137.42 Million USD | -416.373% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -206.104% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -628.891% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -164.96% |
| OPKO Health, Inc. | -157.02 Million USD | -351.931% |
| Exelixis, Inc. | 170.88 Million USD | 515.265% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 382.832% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 761.459% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -1172.735% |
| uniQure N.V. | -282.87 Million USD | -150.866% |
| Imunon, Inc. | -21.03 Million USD | -3274.282% |
| Blueprint Medicines Corporation | -486.27 Million USD | -45.93% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 310.213% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | -81.264% |
| TG Therapeutics, Inc. | 20.63 Million USD | 3539.277% |
| Incyte Corporation | 620.52 Million USD | 214.359% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 2.309% |